Survodutide

Survodutide engages the GLP-1 and glucagon receptors from a single acylated peptide. Its research profile skews toward hepatic models — glucagon receptor agonism increases hepatic fatty acid oxidation, and the published interest in this compound centres on liver fat content rather than glycaemic endpoints alone. That makes it a common comparator in hepatocyte and liver-organoid work.

The practical handling note is counter-ion sensitivity: survodutide is supplied as a TFA salt and residual TFA is cytotoxic above roughly 0.1 % in sensitive cell lines. Our certificate reports residual solvent explicitly rather than leaving you to assume it.